Abstract:Rationale: Circular RNA (circRNA) therapeutics hold great promise as an iteration strategy in messenger RNA (mRNA) therapeutics due to their inherent stability and durable protein translation capability. Nevertheless, the efficiency of RNA circularization remains a significant constraint, particularly in establishing large-scale manufacturing processes for producing highly purified circRNAs. Hence, it is imperative to develop a universal and more efficient RNA circularization system when considering synthetic circRNAs as therapeutic agents with prospective clinical applications. Methods: We initially developed a chimeric RNA circularization system based on the original permuted intron-exon (PIE) and subsequently established a high-performance liquid chromatography (HPLC) method to obtain highly purified circRNAs. We then evaluated their translational ability and immunogenicity. The circRNAs expressing human papillomavirus (HPV) E7 peptide (43-62aa) and dimerized receptor binding domain (dRBD) from SARS-CoV-2 were encapsulated within lipid nanoparticles (LNPs) as vaccines, followed by an assessment of the in vivo efficacy through determination of antigen-specific T and B cell responses, respectively. Results: We have successfully developed a universal chimeric permuted intron-exon system (CPIE) through engineering of group I self-splicing introns derived from Anabaena pre-tRNALeu or T4 phage thymidylate (Td) synthase gene. Within CPIE, we have effectively enhanced RNA circularization efficiency. By utilizing size exclusion chromatography, circRNAs were effectively separated, which exhibit low immunogenicity and sustained potent protein expression property. In vivo data demonstrate that the constructed circRNA vaccines can elicit robust immune activation (B cell and/or T cell responses) against tumor or SARS-CoV-2 and its variants in mouse models. Conclusions: Overall, we provide an efficient and universal system to synthesize circRNA in vitro, which has extensive application prospect for circRNA therapeutics.

Mitigating Cellular Dysfunction by Addressing Contaminants in Synthetic circRNA

Integrated Multiomics Reveals Silencing of Has_circ_0006646 Promotes TRIM21‐Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis

Purifying circular RNA by ultrafiltration

CircRNA-based Therapeutics: Current Opinions and Clinical Potential

Robust genome and cell engineering via in vitro and in situ circularized RNAs

A complete approach for circRNA therapeutics from purification to lyophilized delivery using novel ionizable lipids

Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics

A Simple and Efficient One-Step Synthesis System for Flexible Production of Circular RNA in E. coli

Past, Present and Future: The Relationship Between Circular RNA and Immunity

Analytical Methods and Platforms for circRNA Vector Engineering to Improve Circularization Efficiency

Circular Sirnas for Reducing Off-Target Effects and Enhancing Long-Term Gene Silencing in Cells and Mice

Expanded toolkits for RNA circularization

Engineering circular RNA regulators to specifically promote circular RNA production

Efficient circularization of protein-encoding RNAs via a novel cis -splicing system

Study on the Characterization and Degradation Pattern of Circular RNA Vaccines Using an HPLC Method

Silencing of Hsa_circ_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation of Microrna-214-3p/ezh2 Axis

Effective synthesis of circRNA via a thermostable T7 RNA polymerase variant as the catalyst

Synthetic Circrna Therapeutics: Innovations, Strategies, and Future Horizons

Analytical Methods to Evaluate RNA Circularization Efficiency

Investigating Circular RNAs Using qRT-PCR; Roundup of Optimization and Processing Steps

Chemical circularization of in vitro transcribed RNA opens new avenues for circular mRNA design